Combinational Effect of Angiotensin Receptor Blocker and Folic Acid Therapy on Uric Acid and Creatinine Level in Hyperhomocysteinemia Associated Hypertension

Research output: Contribution to journalArticle

Abstract

Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy), is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, i.e. usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease (IHD) and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors Angiotensin-converting enzyme (ACE) inhibitors and angiotensin converting enzyme inhibitors (ARBs) (except losartan) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia associated hypertension.
LanguageEnglish
Pages1-5
Number of pages5
JournalBiotechnology and Applied Biochemistry
Early online date17 Jul 2019
DOIs
Publication statusE-pub ahead of print - 17 Jul 2019

Fingerprint

Hyperhomocysteinemia
Angiotensin Receptor Antagonists
Uric Acid
Folic Acid
Angiotensin-Converting Enzyme Inhibitors
Creatinine
Hypertension
Acids
Blood
Enzymes
Blood Pressure
Sulfur Amino Acids
Losartan
Endothelial cells
Blood pressure
Homocysteine
Vascular Smooth Muscle
Hematocrit
Sulfur
Methionine

Keywords

  • Hypertension
  • folic acid
  • uric acid
  • hyperhomocysteinemia
  • homocysteine
  • creatinine
  • angiotensin receptor blocker
  • hypertension

Cite this

@article{5960f20034f64b2da2dcb3bb5edd59d9,
title = "Combinational Effect of Angiotensin Receptor Blocker and Folic Acid Therapy on Uric Acid and Creatinine Level in Hyperhomocysteinemia Associated Hypertension",
abstract = "Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy), is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, i.e. usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease (IHD) and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors Angiotensin-converting enzyme (ACE) inhibitors and angiotensin converting enzyme inhibitors (ARBs) (except losartan) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia associated hypertension.",
keywords = "Hypertension, folic acid, uric acid, hyperhomocysteinemia, homocysteine, creatinine, angiotensin receptor blocker, hypertension",
author = "Tambuwala, {Murtaza M}",
year = "2019",
month = "7",
day = "17",
doi = "10.1002/bab.1799",
language = "English",
pages = "1--5",
journal = "Biotechnology and Applied Biochemistry",
issn = "0885-4513",

}

TY - JOUR

T1 - Combinational Effect of Angiotensin Receptor Blocker and Folic Acid Therapy on Uric Acid and Creatinine Level in Hyperhomocysteinemia Associated Hypertension

AU - Tambuwala, Murtaza M

PY - 2019/7/17

Y1 - 2019/7/17

N2 - Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy), is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, i.e. usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease (IHD) and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors Angiotensin-converting enzyme (ACE) inhibitors and angiotensin converting enzyme inhibitors (ARBs) (except losartan) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia associated hypertension.

AB - Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy), is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, i.e. usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease (IHD) and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors Angiotensin-converting enzyme (ACE) inhibitors and angiotensin converting enzyme inhibitors (ARBs) (except losartan) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia associated hypertension.

KW - Hypertension

KW - folic acid

KW - uric acid

KW - hyperhomocysteinemia

KW - homocysteine

KW - creatinine

KW - angiotensin receptor blocker

KW - hypertension

U2 - 10.1002/bab.1799

DO - 10.1002/bab.1799

M3 - Article

SP - 1

EP - 5

JO - Biotechnology and Applied Biochemistry

T2 - Biotechnology and Applied Biochemistry

JF - Biotechnology and Applied Biochemistry

SN - 0885-4513

ER -